CA2897828A1 - Procedes pour identifier et diagnostiquer les lymphomes et predire la duree de leur survie - Google Patents

Procedes pour identifier et diagnostiquer les lymphomes et predire la duree de leur survie Download PDF

Info

Publication number
CA2897828A1
CA2897828A1 CA2897828A CA2897828A CA2897828A1 CA 2897828 A1 CA2897828 A1 CA 2897828A1 CA 2897828 A CA2897828 A CA 2897828A CA 2897828 A CA2897828 A CA 2897828A CA 2897828 A1 CA2897828 A1 CA 2897828A1
Authority
CA
Canada
Prior art keywords
genes
lymphoma
validation
training
gene expression
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA2897828A
Other languages
English (en)
Other versions
CA2897828C (fr
Inventor
Louis M. Staudt
George Wright
Sandeep Dave
Bruce Tan
John I. Powell
Wyndham Wilson
Elaine Jaffe
Wing C. Chan
Timothy C. Greiner
Dennis Weisenburger
James Armitage
Kai Fu
Richard I. Fisher
Lisa Rimsza
Thomas Miller
Thomas Grogan
Elias Campo Guerri
Silvia M. Bea
Itziar Salaverria
Armando Lopez-Guillermo
Emilio Montserrat Costa
Victor Moreno
Andreas Zettl
German Ott
Hans-Konrad Muller-Hermelink
Andreas Rosenwald
Julie Vose
Randy Gascoyne
Joseph Connors
Erlend Smeland
Stein Kvaloy
Harald Holte
Jan Delabie
Andrew Lister
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
British Columbia Cancer Agency BCCA
Julius-Maximilians-University Of Wurzburg
Universitat de Barcelona UB
Fundacio Clinic per a la Recerca Biomedica FCRB
Institut Catala dOncologia
Hospital Clinic de Barcelona
Queen Mary University of London
Oslo Universitetssykehus hf
University of Rochester
University of Arizona
University of Nebraska System
US Department of Health and Human Services
Original Assignee
British Columbia Cancer Agency BCCA
Julius-Maximilians-University Of Wurzburg
Universitat de Barcelona UB
Fundacio Clinic per a la Recerca Biomedica FCRB
Institut Catala dOncologia
Hospital Clinic de Barcelona
Queen Mary and Westfiled College University of London
Oslo Universitetssykehus hf
University of Rochester
University of Arizona
University of Nebraska System
US Department of Health and Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by British Columbia Cancer Agency BCCA, Julius-Maximilians-University Of Wurzburg, Universitat de Barcelona UB, Fundacio Clinic per a la Recerca Biomedica FCRB, Institut Catala dOncologia, Hospital Clinic de Barcelona, Queen Mary and Westfiled College University of London, Oslo Universitetssykehus hf, University of Rochester, University of Arizona, University of Nebraska System, US Department of Health and Human Services filed Critical British Columbia Cancer Agency BCCA
Publication of CA2897828A1 publication Critical patent/CA2897828A1/fr
Application granted granted Critical
Publication of CA2897828C publication Critical patent/CA2897828C/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6842—Proteomic analysis of subsets of protein mixtures with reduced complexity, e.g. membrane proteins, phosphoproteins, organelle proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
    • G16B25/10—Gene or protein expression profiling; Expression-ratio estimation or normalisation
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
    • G16B40/30—Unsupervised data analysis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G01N2333/51—Bone morphogenetic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
    • G16B40/20—Supervised data analysis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
    • Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Medical Informatics (AREA)
  • Pathology (AREA)
  • Organic Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Theoretical Computer Science (AREA)
  • Evolutionary Biology (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Data Mining & Analysis (AREA)
  • Medicinal Chemistry (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • General Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Databases & Information Systems (AREA)
  • Evolutionary Computation (AREA)
  • Public Health (AREA)

Abstract

Des données dexpression génique fournissent une base pour une identification et un diagnostic plus précis des troubles lymphoprolifératifs. De plus, lesdites données peuvent être utilisées pour développer des prédicteurs de survie plus précis. La présente invention concerne des procédés pour identifier et diagnostiquer des lymphomes, et prédire la survie dun lymphome ou dun trouble lymphoprolifératif à partir de motifs dexpression génique. Linvention concerne un nouveau microréseau, le microréseau Lymph Dx, pour obtenir des données dexpression génique à partir dun échantillon de lymphome. Linvention concerne également une diversité de procédés pour utiliser les données dexpression génique de lymphome pour déterminer lidentité dun lymphome particulier et pour prédire la survie dun sujet pour lequel un lymphome particulier a été diagnostiqué. Ces informations seront utiles dans le développement de lapproche thérapeutique à utiliser pour un sujet particulier.
CA2897828A 2006-07-25 2007-07-25 Procedes pour identifier et diagnostiquer les lymphomes et predire la duree de leur survie Active CA2897828C (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11/493,387 2006-07-25
US11/493,387 US8131475B2 (en) 2003-09-03 2006-07-25 Methods for identifying, diagnosing, and predicting survival of lymphomas
CA002659194A CA2659194A1 (fr) 2006-07-25 2007-07-25 Procedes pour identifier et diagnostiquer les lymphomes et predire la duree de leur survie

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CA002659194A Division CA2659194A1 (fr) 2006-07-25 2007-07-25 Procedes pour identifier et diagnostiquer les lymphomes et predire la duree de leur survie

Publications (2)

Publication Number Publication Date
CA2897828A1 true CA2897828A1 (fr) 2008-01-31
CA2897828C CA2897828C (fr) 2022-06-21

Family

ID=38982084

Family Applications (2)

Application Number Title Priority Date Filing Date
CA2897828A Active CA2897828C (fr) 2006-07-25 2007-07-25 Procedes pour identifier et diagnostiquer les lymphomes et predire la duree de leur survie
CA002659194A Abandoned CA2659194A1 (fr) 2006-07-25 2007-07-25 Procedes pour identifier et diagnostiquer les lymphomes et predire la duree de leur survie

Family Applications After (1)

Application Number Title Priority Date Filing Date
CA002659194A Abandoned CA2659194A1 (fr) 2006-07-25 2007-07-25 Procedes pour identifier et diagnostiquer les lymphomes et predire la duree de leur survie

Country Status (4)

Country Link
US (3) US8131475B2 (fr)
EP (2) EP2050035A2 (fr)
CA (2) CA2897828C (fr)
WO (1) WO2008013910A2 (fr)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2526933T3 (pl) 2006-09-22 2015-08-31 Pharmacyclics Llc Inhibitory kinazy tyrozynowej Brutona
US7790631B2 (en) * 2006-11-21 2010-09-07 Intel Corporation Selective deposition of a dielectric on a self-assembled monolayer-adsorbed metal
US8120114B2 (en) 2006-12-27 2012-02-21 Intel Corporation Transistor having an etch stop layer including a metal compound that is selectively formed over a metal gate
US20120101113A1 (en) 2007-03-28 2012-04-26 Pharmacyclics, Inc. Inhibitors of bruton's tyrosine kinase
US12324657B2 (en) 2007-11-28 2025-06-10 Intervet Inc. System and method for diagnosis of bovine diseases using auscultation analysis
CA2726811C (fr) 2008-06-06 2019-11-26 The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services Indice de survie pour un lymphome a grandes cellules b diffus
CA2730930C (fr) 2008-07-16 2015-01-13 Pharmacyclics, Inc. Inhibiteurs de tyrosine kinase de bruton pour le traitement de tumeurs solides
ES2353091B1 (es) * 2009-03-09 2012-01-13 Consejo Superior De Investigaciones Científicas (Csic) Método de diagnóstico diferencial entre el linfoma de burkitt y el linfoma difuso de celulas b grandes.
US8924232B2 (en) * 2009-05-11 2014-12-30 Koninklijke Philips N.V. Device and method for comparing molecular signatures
US20120071497A1 (en) * 2010-06-03 2012-03-22 Pharmacyclics, Inc. Methods of treating abc-dlbcl using inhibitors of bruton's tyrosine kinase
NZ772688A (en) 2010-06-03 2022-09-30 Pharmacyclics Llc The use of inhibitors of bruton’s tyrosine kinase (btk)
WO2013184572A1 (fr) 2012-06-04 2013-12-12 Pharmacyclics, Inc. Formes cristallines d'un inhibiteur de tyrosine kinase de bruton
AU2013293087B2 (en) 2012-07-24 2017-08-31 Pharmacyclics Llc Mutations associated with resistance to inhibitors of Bruton's tyrosine kinase (BTK)
US20150167097A1 (en) 2012-09-20 2015-06-18 Emory University CLASSIFIERS OF NF-kB PATHWAY ACTIVATION, DEVICES, AND METHODS OF USE THEREOF
SG11201503842PA (en) 2012-11-15 2015-06-29 Pharmacyclics Inc Pyrrolopyrimidine compounds as kinase inhibitors
EP2953544B1 (fr) * 2013-02-06 2019-05-08 Intervet Inc. Système pour déterminer l'efficacité d'antibiotique dans des maladies respiratoires à l'aide d'une analyse d'auscultation
WO2014122271A1 (fr) * 2013-02-07 2014-08-14 INSERM (Institut National de la Santé et de la Recherche Médicale) Procédés pour prédire la durée de survie de patients atteints de lymphomes b diffus à grandes cellules
US9421208B2 (en) 2013-08-02 2016-08-23 Pharmacyclics Llc Methods for the treatment of solid tumors
EP3033079B1 (fr) 2013-08-12 2018-10-31 Pharmacyclics LLC Méthodes de traitement d'un cancer amplifié par her2
EP3066215B1 (fr) * 2013-11-06 2019-04-24 The United States of America, represented by the Secretary, Department of Health and Human Services Méthode de sous-typage au sous-type de lymphome au moyen d'expression profilage
KR101473341B1 (ko) * 2014-02-18 2014-12-16 연세대학교 산학협력단 유전자 클래스 결정 방법
CA2942528A1 (fr) 2014-03-20 2015-09-24 Pharmacyclics Inc. Mutations de phospholipase c gamma 2 et associees aux resistances
CA2959602A1 (fr) 2014-08-01 2016-02-04 Pharmacyclics Llc Inhibiteurs de la tyrosine kinase de bruton
US9545407B2 (en) 2014-08-07 2017-01-17 Pharmacyclics Llc Formulations of a bruton's tyrosine kinase inhibitor
EP2995689B1 (fr) 2014-09-11 2017-09-13 Warszawski Uniwersytet Medyczny Stratification de cas de lymphome à cellules B à l'aide d'une signature d'expression génique
IL315294A (en) 2015-03-03 2024-10-01 Pharmacyclics Llc Pharmaceutical formulations of bruton's tyrosine kinase inhibitor
EP3396375B1 (fr) * 2015-12-24 2021-08-04 Konica Minolta, Inc. Dispositif et programme de traitement d'images
CA3021569A1 (fr) 2016-04-20 2017-10-26 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Evaluation du lymphome a cellules du manteau et procedes associes
US11195601B2 (en) 2017-05-31 2021-12-07 International Business Machines Corporation Constructing prediction targets from a clinically-defined hierarchy
WO2018231589A1 (fr) 2017-06-14 2018-12-20 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Procédé de détermination de type de lymphome
JP7357921B2 (ja) * 2017-09-29 2023-10-10 国立大学法人九州大学 びまん性大細胞型ｂ細胞リンパ腫患者における化学療法に対する治療効果を予測するための方法及びキット
MX389484B (es) * 2017-11-13 2025-03-20 The Multiple Myeloma Res Foundation Inc Base de datos, de datos moleculares, omicos, de inmunoterapia, metabolicos, epigeneticos y clinicos, integrados
WO2019152734A1 (fr) * 2018-02-01 2019-08-08 Nantomics, Llc Biomarqueurs dans des nouvelles voies de synthèse de la pyrimidine et chimiorésistance
CN112639475A (zh) * 2018-08-31 2021-04-09 豪夫迈·罗氏有限公司 Dlbcl的预后指数中的胸苷激酶(tk-1)
WO2020056372A1 (fr) 2018-09-14 2020-03-19 Krishnan Ramanathan Cadre d'apprentissage multimodal pour l'analyse d'essais cliniques
WO2020068684A2 (fr) 2018-09-24 2020-04-02 Krishnan Ramanathan Cadre d'analyse hybride pour la prédiction de résultats dans des essais cliniques
WO2020081956A1 (fr) * 2018-10-18 2020-04-23 Medimmune, Llc Procédés de détermination d'un traitement pour des patients atteints d'un cancer
EP3977402A1 (fr) * 2019-05-28 2022-04-06 PAIGE.AI, Inc. Systèmes et procédés de traitement d'images visant à préparer des lames pour des images traitées pour une pathologie numérique
EP3835432A1 (fr) * 2019-12-10 2021-06-16 Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts Gène 1 induit par l'interleukine-4 (il4i1) et métabolites respectifs en tant que biomarqueurs pour le cancer
CN114015773B (zh) * 2021-11-05 2022-06-28 山东第一医科大学附属省立医院(山东省立医院) 全身炎症反应指数在胃肠道弥漫性大b细胞淋巴瘤预后评估中的应用
CN116312778B (zh) * 2023-01-19 2024-02-13 广州医科大学 成熟b细胞肿瘤的辅助诊断预测方法、装置、设备及介质
WO2024181592A1 (fr) * 2023-02-27 2024-09-06 가톨릭대학교 산학협력단 Dispositif de classification de multiples images pour identifier des variations génétiques et procédé de classification associé

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5424186A (en) 1989-06-07 1995-06-13 Affymax Technologies N.V. Very large scale immobilized polymer synthesis
US5242974A (en) 1991-11-22 1993-09-07 Affymax Technologies N.V. Polymer reversal on solid surfaces
US5143854A (en) 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
US5800992A (en) 1989-06-07 1998-09-01 Fodor; Stephen P.A. Method of detecting nucleic acids
US6040138A (en) 1995-09-15 2000-03-21 Affymetrix, Inc. Expression monitoring by hybridization to high density oligonucleotide arrays
US5527681A (en) 1989-06-07 1996-06-18 Affymax Technologies N.V. Immobilized molecular synthesis of systematically substituted compounds
US5744101A (en) 1989-06-07 1998-04-28 Affymax Technologies N.V. Photolabile nucleoside protecting groups
US5252743A (en) 1989-11-13 1993-10-12 Affymax Technologies N.V. Spatially-addressable immobilization of anti-ligands on surfaces
WO1992010588A1 (fr) 1990-12-06 1992-06-25 Affymax Technologies N.V. Mise en sequence par hybridation d'un acide nucleique cible en une matrice d'oligonucleotides determines
DK0604552T3 (da) 1991-09-18 1997-08-04 Affymax Tech Nv Fremgangsmåde til syntese af forskellige samlinger af oligomerer
US5677195A (en) 1991-11-22 1997-10-14 Affymax Technologies N.V. Combinatorial strategies for polymer synthesis
US5384261A (en) 1991-11-22 1995-01-24 Affymax Technologies N.V. Very large scale immobilized polymer synthesis using mechanically directed flow paths
US5550215A (en) 1991-11-22 1996-08-27 Holmes; Christopher P. Polymer reversal on solid surfaces
US5324633A (en) 1991-11-22 1994-06-28 Affymax Technologies N.V. Method and apparatus for measuring binding affinity
US5491074A (en) 1993-04-01 1996-02-13 Affymax Technologies Nv Association peptides
US5837832A (en) 1993-06-25 1998-11-17 Affymetrix, Inc. Arrays of nucleic acid probes on biological chips
US5858659A (en) 1995-11-29 1999-01-12 Affymetrix, Inc. Polymorphism detection
US6090555A (en) 1997-12-11 2000-07-18 Affymetrix, Inc. Scanned image alignment systems and methods
US5631734A (en) 1994-02-10 1997-05-20 Affymetrix, Inc. Method and apparatus for detection of fluorescently labeled materials
US5578832A (en) 1994-09-02 1996-11-26 Affymetrix, Inc. Method and apparatus for imaging a sample on a device
WO1995030774A1 (fr) 1994-05-05 1995-11-16 Beckman Instruments, Inc. Groupements repetes d'oligonucleotides
US5571639A (en) 1994-05-24 1996-11-05 Affymax Technologies N.V. Computer-aided engineering system for design of sequence arrays and lithographic masks
US5795716A (en) 1994-10-21 1998-08-18 Chee; Mark S. Computer-aided visualization and analysis system for sequence evaluation
US5599695A (en) 1995-02-27 1997-02-04 Affymetrix, Inc. Printing molecular library arrays using deprotection agents solely in the vapor phase
US5624711A (en) 1995-04-27 1997-04-29 Affymax Technologies, N.V. Derivatization of solid supports and methods for oligomer synthesis
US5856174A (en) 1995-06-29 1999-01-05 Affymetrix, Inc. Integrated nucleic acid diagnostic device
US5968740A (en) 1995-07-24 1999-10-19 Affymetrix, Inc. Method of Identifying a Base in a Nucleic Acid
JP2000512744A (ja) 1996-05-16 2000-09-26 アフィメトリックス，インコーポレイテッド 標識材料を検出するシステムおよび方法
AU1287799A (en) 1997-10-31 1999-05-24 Affymetrix, Inc. Expression profiles in adult and fetal organs
US5936324A (en) 1998-03-30 1999-08-10 Genetic Microsystems Inc. Moving magnet scanner
JP2004509629A (ja) 2000-09-19 2004-04-02 ホワイトヘッド　インスチチュート　フォアー　バイオメディカル　リサーチ 腫瘍に対する遺伝子マーカー
WO2003021229A2 (fr) 2001-09-05 2003-03-13 The Brigham And Women's Hospital, Inc. Tests diagnostiques et pronostiques
US7371736B2 (en) 2001-11-07 2008-05-13 The Board Of Trustees Of The University Of Arkansas Gene expression profiling based identification of DKK1 as a potential therapeutic targets for controlling bone loss
AU2003261405A1 (en) 2002-11-01 2004-06-07 University Of Massachusetts Regulation of transcription elongation factors
TWI378923B (en) * 2003-08-15 2012-12-11 Novartis Ag Pyrimidine derivatives
ES2368741T3 (es) * 2004-02-25 2011-11-21 Dana-Farber Cancer Institute, Inc. Inhibidores del receptor 1 del factor de crecimiento de tipo insulina para inhibir el crecimiento de células tumorales.
US8603991B2 (en) 2005-11-18 2013-12-10 Gradalis, Inc. Individualized cancer therapy

Also Published As

Publication number Publication date
AU2007277142A1 (en) 2008-01-31
US20120225793A1 (en) 2012-09-06
US10697975B2 (en) 2020-06-30
WO2008013910A3 (fr) 2008-12-24
WO2008013910A2 (fr) 2008-01-31
US20180011106A1 (en) 2018-01-11
EP2299377A1 (fr) 2011-03-23
EP2050035A2 (fr) 2009-04-22
CA2897828C (fr) 2022-06-21
US20070105136A1 (en) 2007-05-10
CA2659194A1 (fr) 2008-01-31
US8131475B2 (en) 2012-03-06

Similar Documents

Publication Publication Date Title
CA2897828C (fr) Procedes pour identifier et diagnostiquer les lymphomes et predire la duree de leur survie
US7711492B2 (en) Methods for diagnosing lymphoma types
US20230395263A1 (en) Gene expression subtype analysis of head and neck squamous cell carcinoma for treatment management
KR20140105836A (ko) 다유전자 바이오마커의 확인
US20190085407A1 (en) Methods and compositions for diagnosis of glioblastoma or a subtype thereof
CN105339797B (zh) 早期乳腺癌的预后预测诊断用基因标记物及其用途
KR20100120657A (ko) Ⅱ기 및 ⅲ기 결장암의 분자적 병기 및 예후
US20250137066A1 (en) Compostions and methods for diagnosing lung cancers using gene expression profiles
CA2684897A1 (fr) Survie au cancer de la prostate et recurrence de ce dernier
Copland et al. The use of DNA microarrays to assess clinical samples: the transition from bedside to bench to bedside
US20110130302A1 (en) Biological pathways associated with chemotherapy outcome for breast cancer
EP1683862B1 (fr) Microreseau d'evaluation de pronostic neuroblastome et procede d'evaluation de pronostic de neuroblastome
CN117355616A (zh) 用于肝细胞癌的dna甲基化生物标志物
US7601532B2 (en) Microarray for predicting the prognosis of neuroblastoma and method for predicting the prognosis of neuroblastoma
AU2007277142B2 (en) Methods for identifying, diagnosing, and predicting survival of lymphomas
AU2012200939B2 (en) Methods for identifying, diagnosing, and predicting survival of lymphomas
AU2014200767B2 (en) Methods for identifying, diagnosing, and predicting survival of lymphomas

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20150721